EHang Holdings Ltd - ADR vs Novavax Inc — how do they compare? EHang Holdings Ltd - ADR trades at $5.78 (market cap $435.35M), while Novavax Inc trades at $7.97 (market cap $1.30B). The key difference: Novavax Inc is far larger — about 3× EHang Holdings Ltd - ADR's market cap, and Novavax Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| EH | NVAX | |
|---|---|---|
Market Cap | $435.35M | $1.30B |
Sector | Industrials | Health |
52-Week High | $19.44 | $11.19 |
52-Week Low | $4.90 | $6.22 |
Enterprise Value | $374.58M | $879.40M |
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $5.74, up 7.69% in the last session, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported Q1 2026 revenue of $418 million, flat year-over-year, but with a significant net loss of $276 million, reflecting ongoing profitability challenges despite a high gross margin of 61.53%. Recent news highlights operational progress, including the first pilotless eVTOL flight in Central Asia, but the stock remains volatile amid sector-wide pressures.
The outlook for EH is highly speculative, with substantial execution risks and negative earnings overshadowing long-term potential in the advanced air mobility market. Analyst sentiment is divided, with a consensus price target of $6.97 offering limited upside, while institutional ownership trends and cash flow volatility underscore the high-risk nature of the investment.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →